Search research articles
Contact Us
Filters
Showing results (51-60 of 66) with videos related to
Page
of 7
Sort By:
Transplantation and Cellular Therapy
|
January 1, 2026
ASTCT Clinical Practice Recommendations for Transplantation in Classical Hodgkin Lymphoma
Sairah Ahmed, Ambuj Kumar, Paul Carpenter, et al.
Haematologica
|
September 5, 2024
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience
Giulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, et al.
Blood
|
February 16, 2023
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL
Jia Ruan, Alison Moskowitz, Neha Mehta-Shah, et al.
Blood Cancer Journal
|
June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
Sabela Bobillo, Erel Joffe, David Sermer, et al.
Blood Advances
|
July 30, 2020
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma
David Sermer, Sabela Bobillo, Ahmet Dogan, et al.
Haematologica
|
October 30, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R
Brian Hess, Alison Moskowitz, James A Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Caitlin M Stewart, Laure Michaud, Karissa Whiting, et al.
Haematologica
|
November 27, 2025
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma
Erel Joffe, Manik Uppal, Serena Zheng, et al.
Blood
|
July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
Sabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
Blood
|
October 22, 2024
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
Anita Kumar, Jacob Soumerai, Jeremy S Abramson, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 66) with videos related to
Sort By:
Page
of 7
Transplantation and Cellular Therapy
|
January 1, 2026
ASTCT Clinical Practice Recommendations for Transplantation in Classical Hodgkin Lymphoma
Sairah Ahmed, Ambuj Kumar, Paul Carpenter, et al.
Haematologica
|
September 5, 2024
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience
Giulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, et al.
Blood
|
February 16, 2023
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL
Jia Ruan, Alison Moskowitz, Neha Mehta-Shah, et al.
Blood Cancer Journal
|
June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
Sabela Bobillo, Erel Joffe, David Sermer, et al.
Blood Advances
|
July 30, 2020
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma
David Sermer, Sabela Bobillo, Ahmet Dogan, et al.
Haematologica
|
October 30, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R
Brian Hess, Alison Moskowitz, James A Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Caitlin M Stewart, Laure Michaud, Karissa Whiting, et al.
Haematologica
|
November 27, 2025
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma
Erel Joffe, Manik Uppal, Serena Zheng, et al.
Blood
|
July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
Sabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
Blood
|
October 22, 2024
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
Anita Kumar, Jacob Soumerai, Jeremy S Abramson, et al.
Page
of 7